Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9570172 | 0.81 | — | — | |
| SCHEMBL80155 | 0.72 | CTSA (0.56) | CTSAACHEALDH1A1L3MBTL1KDM4E | |
| SCHEMBL1935140 | 0.69 | CTSA (0.53) | CTSAACHEALDH1A1L3MBTL1KDM4E | |
| SCHEMBL10308497 | 0.69 | — | — | |
| Methylphosphonic Acid Diisopropyl Ester SCHEMBL472052 | 0.69 | CTSA (0.53) | CTSAACHEALDH1A1L3MBTL1KDM4E | |
| SCHEMBL25174107 | 0.69 | CTSA (0.53) | CTSAACHEALDH1A1L3MBTL1KDM4E | |
| SCHEMBL4905870 | 0.67 | CTSA (0.43) | CTSAACHEALDH1A1L3MBTL1KDM4E | |
| SCHEMBL10395342 | 0.67 | CTSA (0.43) | CTSAACHEALDH1A1L3MBTL1KDM4E | |
| SCHEMBL3133686 | 0.67 | — | — | |
| Phosphorylisopropane SCHEMBL82996 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-58032890-A | — | — | None | — | — | JP | disclosed |
| EP-3483143-B1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2023-10-18 | — | — | EP | disclosed |
| EP-4251633-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-10-04 | — | — | EP | disclosed |
| EP-4092012-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20220169611-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2022-06-02 | — | — | US | disclosed |
| WO-2022109741-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2022-06-02 | — | — | WO | disclosed |
| US-20210179560-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2021-06-17 | — | — | US | disclosed |
| EP-3483143-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | Amgen, Inc (US) | 2019-05-15 | — | — | EP | disclosed |
| CN-107820499-A | Novel antiviral compounds, process for their preparation and their use for the treatment of viral infections | 鲁汶大学研究与开发部 | 2018-03-20 | — | — | CN | disclosed |
| US-20170144971-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-6245779-B1 | ANALGESICS; ANTIINFLAMMATORY AGENTS | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2001-06-12 | — | — | US | disclosed |
| EP-1049684-A1 | NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-11-08 | — | — | EP | disclosed |
| WO-2000050414-A1 | NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | DR.REDDY'S RESEARCH FOUNDATION (IN) | 2000-08-31 | — | — | WO | disclosed |
| EP-0997463-A1 | NAPHTHYRIDINE DERIVATIVES | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999019313-A1 | NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-04-22 | — | — | WO | disclosed |
| US-5707997-A | ANALGESICS | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1998-01-13 | — | — | US | disclosed |
| EP-0714898-A1 | PYRAZOLO [1,5-a]PYRIMIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1996-06-05 | — | — | EP | disclosed |
| US-5270322-A | Imidazo[1,2-a]pyridines, pharmaceutical compositions containing these compounds and processes for preparing them | DR. KARL THOMAE GMBH (DE) | 1993-12-14 | — | — | US | disclosed |
| EP-0555825-A1 | Imidazo(1,2-a)pyridines as angiotensin-II-antagonists | Dr. Karl Thomae GmbH (DE) | 1993-08-18 | — | — | EP | disclosed |
| JP-S5832890-A | PHOSPHONIC ESTER DERIVATIVE, ITS PREPARATION, HEBICIDE CONTAINING THE SAME AS ACTIVE INGREDIENT | SUMITOMO CHEM CO LTD | 1983-02-25 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169611-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | CTSA 2418/4885ACHE 4496/4885ALDH1A1 332/4885 |
| US-20210179560-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | CTSA 2418/4885ACHE 4496/4885ALDH1A1 332/4885 |
| US-20170144971-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | CTSA 2418/4885ACHE 4496/4885ALDH1A1 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.